Rarer Cancer Forum have produced a booklet to advice consultants on appealing negative funding decisions from PCT's...download booklet here
Capsule Summary CCO Independent Conference Coverage of the American Society of Hematology 2008 Annual Meeting*
Cytogenetic Response to Dasatinib Predictive for Progression-Free Survival in Imatinib-Resistant/Intolerant CML Patients
Posting Date: December 12, 2008
Analysis[1] of pooled data from 2 phase II clinical trials: SRC-ABL Tyrosine Kinase Inhibition Activity Research Trial (START)–C and START-R
Summary of Key Conclusions
Cytogenetic responses rapidly attained with dasatinib 70 mg twice daily in imatinib-resistant/intolerant patients with chronic-phase chronic myeloid leukemia (CML)
89% of all complete cytogenetic responses achieved within first 12 months of treatment
47% of responses achieved within first 3 months of treatment
Cytogenetic responses highly durable with dasatinib therapy
91% of complete cytogenetic responses maintained during 24 months of follow-up
Achieving both major cytogenetic response and complete cytogenetic response at 12 months highly predictive for PFS
Summary Friday, December 19, 2008
Capsule SummaryCCO Independent Conference Coverage of the American Society of Hematology 2008 Annual Meeting*
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
CCO Independent Conference Coverage of the American Society of Hematology 2008 Annual Meeting*
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
These letters are templates which you can use when writing to your PCT and MP when challenging negative funding decisions for alternatives to imatinib. f You should change the wording to suit your individual details and situation.
Scientists may be able to stop cancer spreading round the body
Scientists have discovered how cancer spreads round the body raising the possibility it could be stopped.
New RCF report reveals striking postcode lottery in the chances of having an exceptional request for cancer treatment approved
Monday, August 11, 2008
Rarer Cancers Forum carried out an audit of the policies and processes used by PCTs to determine exceptional funding requests. The audit found that:
YOUR PATIENT'S RIGHT TO TREATMENT,
written by Peter Telford
Your Patient's Right to Treatment: Applying for NHS Exceptional Funding for Treatment
This 32-page booklet was written by a barrister, Peter Telford. It was launched at
Novel Agents in CML Therapy:
Tyrosine Kinase Inhibitors and Beyond
Junia V. Melo (2) and Charles Chuah (1)
Press Release Source: Novartis Pharmaceuticals UK Ltd
Data Shows Longest Ever Survival for Patients With Life-Threatening Leukaemia Treated With Breakthrough Treatment
Monday December 8, 5:00 pm ET
- 86 Percent of Patients With Ph+ Chronic Myeloid Leukaemia
Treated With Breakthrough Treatment Glivec(R) are Alive After Seven Years(1)
- Treatment Shown to Slow Disease Progression: Only one Patient
out of 317 Experienced Disease Progression Between Year Six and Seven of
Treatment(1)
- Data Demonstrate Longest Overall Survival Observed to Date in
This Disease Area